


EQUIPD Basic Results Summary

Participant flow:



Baseline characteristics:

Table: Baseline Characteristics of the Cohort (patient-level)

Characteristic	Control n = 6010	QIC n = 11065	Overall n = 17075
Sex			
Female	2705 (45.0%)	5155 (46.6%)	7860 (46.0%)
Male	3300 (54.9%)	5915 (53.5%)	9215 (54.0%)
Ethnicity			
Asian or Asian British	425 (7.1%)	655 (5.9%)	1075 (6.3%)
Black or Black British	285 (4.7%)	330 (3.0%)	615 (3.6%)
Mixed	85 (1.4%)	140 (1.3%)	225 (1.3%)
Other/not stated	90 (1.5%)	440 (4.0%)	530 (3.1%)
White	5125 (85.3%)	9505 (85.9%)	14630 (85.7%)
IMD Quintile[†]			
1	1335 (22.2%)	3570 (32.3%)	4905 (28.7%)
2	1355 (22.5%)	2345 (21.2%)	3700 (21.7%)
3	1315 (21.9%)	1970 (17.8%)	3290 (19.3%)
4	1150 (19.1%)	1800 (16.3%)	2950 (17.3%)
5	850 (14.1%)	1380 (12.5%)	2230 (13.1%)
Age, years			
Mean (SD)	48.28 (17.01)	49.14 (17.30)	48.84 (17.21)
Median (Min, Max) (Q1, Q3)	49.00 (18.00, 99.00) (34.00, 60.00)	50.00 (18.00, 99.00) (35.00, 62.00)	50.00 (18.00, 99.00) (34.00, 61.00)
Duration of diabetes, years			
Mean (SD)	20.50 (13.24)	20.49 (12.95)	20.49 (13.05)
Median (Min, Max) (Q1, Q3)	18.00 (1.00, 89.00) (10.00, 28.00)	18.00 (0.00, 79.00) (11.00, 27.00)	18.00 (0.00, 89.00) (11.00, 27.00)
Missing	<5 (<0.1%)	<5 (<0.1%)	<5 (<0.1%)
Days between baseline HbA1c measurement and randomisation			
Mean (SD)	130.91 (98.16)	134.10 (98.34)	132.98 (98.28)
Median (Min, Max) (Q1, Q3)	106.00 (1.00, 365.00) (45.00, 203.00)	114.00 (1.00, 365.00) (49.00, 206.00)	112.00 (1.00, 365.00) (49.00, 205.00)
Baseline HbA1c value			
Mean (SD)	85.26 (14.76)	86.12 (15.31)	85.82 (15.13)
Median (Min, Max) (Q1, Q3)	81.00 (69.40, 173.00) (74.00, 92.00)	82.00 (69.40, 190.00) (75.00, 93.00)	81.00 (69.40, 190.00) (75.00, 92.00)

[†] For Index of Multiple Deprivation (IMD), 1 = most deprived, 5 = least deprived

Primary Outcome Measure:

Analysis	Control	QIC	QIC vs Control	
	95% CI: Odds	95% CI: Odds	95% CI: Odds Ratio	p-value
Primary	0.0191 (0.0131, 0.0279)	0.0150 (0.0111, 0.0202)	0.7841 (0.5061, 1.2146)	0.2760

The estimated difference in probability of being established on an insulin pump (for QIC compared to control) was -0.69% (95% CI: -1.97% to 0.60%) with a p-value of 0.296. There was no evidence of a statistical difference in the odds of being established on insulin between the control and intervention arms.

Adverse Events:

Events fulfilling the definition of an adverse event or serious adverse were not reportable in this study unless they fulfilled the definition of a Related and Unexpected Serious Adverse Event (RUSAE). No Related Unexpected Serious Adverse Events (RUSAEs) were reported during the study.

Deaths were reported during the trial period; however, deaths were recorded as part of the National Diabetes Audit. Of the 17075 patients in our cohort, there were 1135 (6.65%) deaths, 400 (6.66%) in the control arm and 735 (6.64%) in the QIC arm.

Acronyms:

CI: Confidence interval

IMD: Index of Multiple Deprivation

QIC: Quality Improvement Collaborative

RUSAE: Related Unexpected Serious Adverse Events